Report #2858653

Received Sep 15, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Not recovered
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
UNK	VACCINE NOT SPECIFIED (NO BRAND NAME)	UNKNOWN MANUFACTURER	UNK	UNK	—

Symptoms (1)

Pain

Symptom narrative

Sore; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in a patient who received RSVPreF3 adjuvanted (AREXVY-GSK) for prophylaxis. On an unknown date, the patient received AREXVY-GSK. On an unknown date, an unknown time after receiving AREXVY-GSK, the patient experienced pain (Verbatim: Sore). The outcome of the pain was not resolved. It was unknown if the reporter considered the pain to be related to AREXVY-GSK. It was unknown if the company considered the pain to be related to AREXVY-GSK. Additional Information: GSK receipt date: 16-AUG-2025 This case was reported by a patient via interactive digital media.